Investigating ways to enhance RNA editing for treating diseases.
Nucleic acid modulators and theranostics for ADAR
['FUNDING_OTHER'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10936543
This study is exploring how to improve the work of a special enzyme called ADAR that helps edit RNA in our bodies, with the goal of creating new treatments for conditions like blood clotting issues and certain types of cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10936543 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding and enhancing the function of a specific enzyme called ADAR, which edits RNA molecules in the body. By using innovative tools like RNA nano-reporters, the team aims to profile ADAR activity in living organisms and develop therapies that can modulate its function. The approach includes using specially designed DNA and RNA molecules to promote ADAR activity and deliver these treatments effectively to target tissues. The research also involves testing these therapies in mouse models of specific diseases, such as Factor V Leiden thrombophilia and metastatic melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with genetic disorders caused by specific mutations or those diagnosed with certain types of cancer.
Not a fit: Patients with conditions unrelated to RNA editing or those not affected by the diseases being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for genetic disorders and improve cancer treatments by harnessing the body's own RNA editing mechanisms.
How similar studies have performed: Previous research has shown promise in using RNA editing technologies for therapeutic purposes, indicating a potential for success in this novel approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, GUIZHI — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: ZHU, GUIZHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.